OncoMatch/Clinical Trials/NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Is NCT07419295 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments for bladder cancer.
Treatment: Sacituzumab tirumotecan · Vinflunine · Docetaxel · Paclitaxel · Rescue medications for sacituzumab tirumotecan · Rescue medications for chemotherapy — Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Urothelial Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-pd-1 therapy
Must have received: platinum-based chemotherapy
Must have received: antibody-drug conjugate (enfortumab vedotin)
Cannot have received: trop2-targeted antibody-drug conjugate
Cannot have received: topoisomerase 1 inhibitor-containing antibody-drug conjugate
Cannot have received: chemotherapy for urothelial cancer (paclitaxel, docetaxel, vinflunine)
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Munson Medical Center ( Site 0812) · Traverse City, Michigan
- TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0822) · Cincinnati, Ohio
- The West Clinic, P.C. ( Site 0791) · Germantown, Tennessee
- Thompson Cancer Survival Center ( Site 0803) · Knoxville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07419295 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior trop2-targeted antibody-drug conjugate, topoisomerase 1 inhibitor-containing antibody-drug conjugate, chemotherapy for urothelial cancer disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages